Compare GPMT & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | VTGN |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 122.1M |
| IPO Year | 2017 | N/A |
| Metric | GPMT | VTGN |
|---|---|---|
| Price | $2.67 | $4.24 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.13 | N/A |
| AVG Volume (30 Days) | 139.4K | ★ 1.0M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | ★ 7.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | $21.74 | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.61 | $1.90 |
| 52 Week High | $3.45 | $5.14 |
| Indicator | GPMT | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 50.22 |
| Support Level | $2.73 | $3.91 |
| Resistance Level | $2.82 | $4.60 |
| Average True Range (ATR) | 0.08 | 0.47 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 40.00 | 50.00 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.